Array BioPharma Inc

Type: Company
Name: Array BioPharma Inc
Nationality: United States
Web Address: http://www.arraybiopharma.com/
First reported 17 hours ago - Updated 17 hours ago - 1 reports

Oncothyreon Reports Second Quarter 2014 Financial Results

By a News Reporter-Staff News Editor at Biotech Week -- Oncothyreon Inc. (NASDAQ: ONTY) reported financial results for the second quarter ended June 30, 2014 (see also Biotechnology Companies ).Loss from operations decreased to $7.8 million for the three ... [Published HispanicBusiness.com - 17 hours ago]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Array BioPharma Falls Despite Narrower-than-Expected Q4 Loss

Share price of Array BioPharma Inc. ( ARRY ) fell 5.1% after the company announced its fiscal fourth quarter results on Aug 12. Shares lost a further 2.6% thereafter.Array BioPharma reported a loss of 22 cents per share in the fourth quarter of fiscal ... [Published Yahoo! Finance - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

ARRAY BIOPHARMA INC - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our ... ... [Published Street Sweeper - Aug 15 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Array Biopharma Inc gives Q1 2015 guidance below analysts' estimates - Conference call

Tue, Aug 12 2014Array Biopharma Inc:Sees Q1 2015 revenue and loss per share (EPS) to be similar to Q4 2014.Reported revenue of $6.01 mln and EPS of $(0.22) in Q4 2014.Q1 2015 revenue of $10.06 mln and EPS of $(0.21) - Thomson Reuters I/B/E/S. ... [Published Reuters UK - Aug 13 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Leerink Swann Reiterates Outperform Rating for Array BioPharma (ARRY)

Separately, analysts at Cantor Fitzgerald initiated coverage on shares of Array BioPharma in a research note on Thursday, May 29th. They set a “buy” rating and a $9.00 price target on the stock.Shares of Array BioPharma (NASDAQ:ARRY) traded down 2.57% ... [Published American Banking News - Forex - Aug 13 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 3 reports

Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2014

BOULDER, Colo., Aug. 12, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ending June 30, 2014.Ron Squarer, Chief Executive Officer of Array, noted, "The Array-invented ... [Published Bio-Medicine - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Array BioPharma (ARRY) Set to Announce Earnings on Tuesday

Array BioPharma (NASDAQ:ARRY) will be releasing its Q414 earnings data on Tuesday, August 12th. Analysts expect Array BioPharma to post earnings of ($0.23) per share and revenue of $8.10 million for the quarter. Persons that are interested in registering ... [Published American Banking News - Forex - Aug 11 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 2 reports

Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2014 On August 12, 2014

First reported Jul 23 2014 - Updated Jul 24 2014 - 4 reports

Array BioPharma, Inc. (ARRY) Jumps: Stock Surges 10.7% Higher - Tale of the Tape

Array BioPharma, Inc. ( ARRY ) was a big mover last session, as the company saw its shares rise by nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend ... [Published Zacks.com - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 2 reports

Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

Midway through trading Wednesday, the Dow traded down 0.18 percent to 17,082.38 while the NASDAQ surged 0.41 percent to 4,474.24. The S&P also rose, gaining 0.19 percent to 1,987.23. Leading and Lagging Sectors In trading on Wednesday, healthcare shares ... [Published DailyMe.Com - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 3 reports

WEDNESDAY'S ETF MOVERS : Xbi, soxx

In trading on Wednesday, the SPDR S&P Biotech ETF (XBI) is outperforming other ETFs, up about 6.3% on the day. Components of that ETF showing particular strength include shares of Puma Biotechnology (PBYI), up about 291.1% and shares of Array Biopharma ... [Published 4 Traders - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 2 reports

Markets Mixed; PepsiCo Q2 Earnings Beat Street View

Following the market opening Wednesday, the Dow traded down 0.23 percent to 17,073.50 while the NASDAQ surged 0.22 percent to ...Related Stocks:Array Biopharma, Inc. BIOGEN IDEC Inc. Conmed Corp Intuitive Surgical Inc. JUNIPER NETWORKS, Inc. Knightsbridge ... [Published Minyanville - Jul 23 2014]

Quotes

Dr. Kay continued, "The results of this study suggest that one may be able to treat patients who have had breast cancer treated appropriately with a TNF inhibitor without significant risk of recurrence of that malignancy. As a result, patients with rheumatoid arthritis may be able to receive appropriate treatment for their joint disease, regardless of their history of breast cancer."
Ron Squarer, Chief Executive Officer of Array, noted, "The Array-invented MEK inhibitors, binimetinib and selumetinib, are currently enrolling six Phase 3 trials, and each of our partners has announced expectations for regulatory filings next year. In addition, we continue to advance our wholly-owned filanesib program, which has the potential to be an important novel treatment for patients with multiple myeloma. Given the progress on our key programs and the possible return of binimetinib to Array, we are looking forward to an exciting year."
Ron Squarer, Chief Executive Officer of Array, noted, "The Array-invented MEK inhibitors,... "
"I also believe in the potential of Oncothyreon's existing pipeline, including ONT-380 for HER2-positive breast cancer, and the immunotherapeutic product candidates, tecemotide and ONT-10."

More Content

All (87) | News (53) | Reports (0) | Blogs (26) | Audio/Video (0) | Fact Sheets (0) | Press Releases (8)
sort by: Date | Relevance
Oncothyreon Reports Second Quarter 2014 Financi... [Published HispanicBusiness.com - 17 hours ago]
First Week of October 18th Options Trading For ... [Published TVNewsCheck - Aug 19 2014]
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
TNF Inhibitors for RA: No Link to Breast Cancer [Published Diabetes Care - Aug 18 2014]
Array BioPharma Falls Despite Narrower-than-Exp... [Published Yahoo! Finance - Aug 15 2014]
ARRAY BIOPHARMA INC - 10-K - MANAGEMENT'S DISCU... [Published Street Sweeper - Aug 15 2014]
Array Biopharma Inc gives Q1 2015 guidance belo... [Published Reuters UK - Aug 13 2014]
Stock Analysts’ Ratings Reiterations for August... [Published Mideast Time - Aug 13 2014]
Leerink Swann Reiterates Outperform Rating for ... [Published American Banking News - Forex - Aug 13 2014]
Boulder's Array BioPharma reports wider losses,... [Published TVNewsCheck - Aug 13 2014]
Array BioPharma's (ARRY) CEO Ron Squarer on Q4 ... [Published Seeking Alpha - Aug 12 2014]
Today's Stock Market News Driven by AMZN Spat a... [Published Money Morning - Aug 12 2014]
Array BioPharma (ARRY) Releases Quarterly Earni... [Published American Banking News - Earnings - Aug 12 2014]
Array BioPharma Reports Financial Results For T... [Published Bio-Medicine - Aug 12 2014]
Array BioPharma Reports Financial Results For T... [Published Nasdaq - Aug 12 2014]
Array BioPharma Reports Financial Results For T... [Published TickerTech.com - Aug 12 2014]
Array BioPharma Reports Financial Results For T... [Published Financial Services - Aug 12 2014]
Oncothyreon purchases Alpine Biosciences for US... [Published Manufacturing Chemist - Aug 12 2014]
Earnings Scheduled For August 12, 2014 [Published Minyanville - Aug 12 2014]
Earnings Scheduled For August 12, 2014 [Published Benzinga.com - Aug 12 2014]
Oncothyreon reports decreased net operating los... [Published News-Medical.Net - Aug 12 2014]
Oncothyreon's (ONTY) CEO Robert Kirkman on Q2 2... [Published Seeking Alpha - Aug 12 2014]
Oncothyreon Announces Acquisition of Alpine Bio... [Published TickerTech.com - Aug 11 2014]
Array BioPharma (ARRY) Set to Announce Earnings... [Published American Banking News - Forex - Aug 11 2014]
Array BioPharma (ARRY) Orphan Drug Status for O... [Published Live-PR.com - Aug 01 2014]
Amgen closing Longmont, Boulder facilities [Published Burlington Record - Jul 30 2014]
Allergic Rhinitis Market: New Industry Research... [Published MyNewsDesk - Jul 29 2014]
All About Crystals: Tiny, Giant, from Mars, fro... [Published Bio-Medicine - Jul 28 2014]
Array BioPharma To Report Financial Results For... [Published Bio-Medicine - Jul 28 2014]
Array BioPharma To Report Financial Results For... [Published Indianapolis Business Journal - Jul 28 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Array BioPharma To Report Financial Results For... [Published PR Newswire: Health - Jul 28 2014]
BOULDER, Colo., July 28, 2014  Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the fourth quarter and full year of fiscal 2014 and hold a conference call to discuss those results on Tuesday, August 12, 2014.  Ron Squarer, Chief ...
Array BioPharma To Present At The Wells Fargo S... [Published PR Newswire: General Business - Jun 11 2014]
BOULDER, Colo., June 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities 2014 Healthcare Conference in Boston.  The public is welcome ...
Frontrunning: May 30 [Published Zero Hedge - May 30 2014]
Ukraine Rebels Outfox Army to Dent Poroshenko Troop Goal ( BBG ) Russia Withdraws Most of Forces From Ukraine Border: U.S. ( BBG ) Super-Size Me! China’s ’Mini’ Stimulus Starts Expanding ( BBG ) Option B: The blueprint for Thailand's coup ( Reuters ) ...
Array BioPharma, Biogen Idec enter drug discove... [Published PBR - News - May 29 2014]
US-based biopharmaceutical firm Array BioPharma has entered into collaboration agreement with Biogen Idec to discover and develop inhibitors targeting a new kinase for the treatment of autoimmune disorders. ...
Array BioPharma Announces Drug Discovery Collab... [Published PR Newswire: Health - May 28 2014]
BOULDER, Colo., May 28, 2014 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY) announced today a collaboration agreement with Biogen Idec (NASDAQ: BIIB) for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Array BioPharma Reports Financial Results For T... [Published Financial Services - Aug 12 2014]
Biotech Stocks Highlight -- Research on Celgene... [Published Financial Services - Jul 09 2014]
Study Updates, Market Activity, Preclinical Dat... [Published Financial Services - Jul 03 2014]
Health Care Sector Equities Coverage -- Researc... [Published Financial Services - Jun 06 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.